

Jessica E. Thaxton, PhD, MsCR
Associate Professor
Department of Cell Biology & Physiology
Joint Faculty, Microbiology & Immunology
University of North Carolina at Chapel Hill

125 Mason Farm Road, Marsico Hall, 5229M/N
University of North Carolina, Chapel Hill, 27514
jess_thaxton@med.unc.edu
<https://www.thaxtonimmuno.com/>

Expertise

Cancer immunologist studying how cellular stress and organelle biology shape immune dysfunction in cancer. Her research defines a cell biological framework for understanding how the tumor microenvironment alters immune cell function through changes in stress signaling, metabolic state, and organelle architecture. Her laboratory integrates tumor immunology, immunometabolism, cell biology, and stress biology to uncover fundamental mechanisms of immune dysfunction and identify new strategies for cancer immunotherapy.

Leadership & Academic Appointments

Chair, Awards Review Committee Society for Immunotherapy of Cancer	2026-PRES
Director & Creator, Cancer Grants Studio Junior Faculty Grant Development Program University of North Carolina, Chapel Hill, NC	2025-PRES
Joint Faculty, Department of Microbiology & Immunology University of North Carolina, Chapel Hill, NC	2025-PRES
Co-Chair, Awards Review Committee Society for Immunotherapy of Cancer	2024-2026
Co-Leader, Cancer Cell Biology Program, Lineberger Comprehensive Cancer Center University of North Carolina, Chapel Hill, NC	2024-PRES
Co-Chair, Translational Immune Oncology Study Section National Cancer Institute, USA	2024-PRES
Standing Member, Translational Immune Oncology Study Section National Cancer Institute, USA	2024-PRES
Associate Professor, Department of Cell Biology & Physiology University of North Carolina, Chapel Hill, NC	2022-PRES
Assistant Professor, Medical University of South Carolina, Charleston, SC Departments of Orthopedics, Microbiology & Immunology	2017-2021
Post-doctoral Fellow, Medical University of South Carolina, Charleston, SC Department of Microbiology & Immunology	2012-2016
Post-doctoral Fellow, Oregon Health & Sciences University, Portland, OR Department of Microbiology & Immunology	2010-2012
Graduate Student, Brown University, Providence, RI Department of Microbiology & Immunology	2004-2009

Research Funding Portfolio

Revised 07/22/2026

Active Grants:

MF-2601-11979, Mathers Foundation ER Architecture as a Determinant of T Cell Metabolism in Cancer Role: PI	09/01/2026 – 08/31/2029 \$700,000
R01CA310022A, NIH/NCI Regulation of Immunometabolism by the Integrated Stress Response in Cancer Role: PI	04/01/2026 – 03/31/2031 \$3,791,819
R01CA288976A1, NIH/NCI Manipulating Lipid Metabolism to Reverse Immune Dysfunction in Cancer Role: PI	12/01/2024-11/30/2029 \$2,105,180
R01CA305975A1, NIH/NCI Mechanisms of ATF4-Macrophage Dysfunction in Cancer Role: MPI (Thaxton/ Guerriero)	07/06/2026 – 06/30/2031 \$3,990,063
V Foundation, Adult Translational Grant The Cellular Response to Stress as A Mechanism of ICI Resistance in Cancer Role: PI	07/15/2025 – 07/14/2029 \$800,000
R61CA309698-01, NIH/NCI Multiplexed multiscale imaging for cellular immunotherapies PI: Legant Role: Co-I	04/01/2026 – 03/31/2029 \$699,275
R37 CA269499-01, NIH/NCI Immunometabolic Pathways Enabled by PARP Inhibition in Breast Cancer PI: Guerriero Role: Co-I	04/01/2022-03/31/2027 \$143,806
5-P30-CA016086-43 Cancer Center Support Grant PI: Ferris Role: Program Co-Leader	06/01/1997 - 11/30/2027 \$41,436
SPORE, NIH/NCI Yale-UNC HNSCC SPORE MPI: Ferris, Burtness Role: Co-I, Project 2	09/01/2026-08/31/2031 \$41,436
R01 Not Assigned-A1-01, NIH/NCI ADCK3 and MAP3K4 as repressors of CAR-T cell stemness PI: Dotti Role: Co-I	09/01/2026 – 08/31/2031 \$41,436

Scientific Publications

1. Green WD, Gomez A, Merritt E, Pratt BM, Green JM, Beckabir W, Whately K, Tsahouridis O, Cui X, Fecci PE, Vincent B, Kim WY, Dotti G, Pecot C, **Thaxton JE**, Morris JP, Milner JJ. A single-platform orthotopic immune atlas across murine tumor models. *Under review, Nature Chemical Biology*. Mullins GN, Pratt BM, Brown N, Green WD, Modliszewski J, Xie F, Van Rooyen L, Zhabotynsky V, Green JM, Shi H, Merritt E, Egawa T, Somasundaram A, **Thaxton JE**, Dotti G, Chung HK, Milner JJ. Latent Regulatory Programs Generate Synthetic T Cell States with Enhanced Therapeutic Potential. <https://www.biorxiv.org/content/10.64898/2026.01.07.698190v1.full>. *In revision, Nature*.

Revised 07/22/2026

2. Kennedy AS, Clutton GT, Hunt EG, Hem JW, Alicea Pauneto CDM, Riesenberger BP, Green JM, Hurst KE, Hagle RS, Sheft LS, Zhou X, Esther RJ, Knochelmann HM, Paulos CM, Neskey D, Cubillos-Ruiz J, Savoldo B, Dotti G, Earp HS, Trivedi S, Liu Y, Green WD, Milner JJ, Genereux JC, Salmon WC, Wiseman RL, **Thaxton JE**. Tumor Stress Rewires Endoplasmic Reticulum Architecture to Enforce T Cell Dysfunction. *In Press, Immunity*. 2026
3. Walhart T, Song F, Biondi M, Stucchi S, Li G, Peishun P, Suzuki K, Hunt EG, Kennedy AS, **Thaxton JE**, Withers T, Hunsucker S, Tsahouridis R, Serafini M, Flick L, Lichtman EI, Woodcock M, Su L, Yang Z, Xiong G, Cui Z, Wang P, Liu C, Savoldo B, Armistead P, Dotti G. High-avidity Cathepsin-G specific CAR-T cells for the treatment of Acute Myeloid Leukemia. *Blood*. 2026
4. Chung HK, Liu C, Jambor AN, Riesenberger BP, Sun M, Casillas E, Chick B, Wang A, Wang J, Ma S, McDonald B, He P, Yang Q, Chen T, Varanasi SK, LaPorte M, Mann TH, Chen D, Hoffmann F, Tripple V, Ho J, Modliszewski J, Williams A, Cho UH, Liu L, Wang Y, Hargreaves DC, **Thaxton JE**, Milner JJ, Kaech SM, Wang W. Atlas-Guided Discovery of Transcription Factors for T Cell Programming. *bioRxiv*. 2025 Jan 4; doi: 10.1101/2023.01.03.522354. PubMed PMID: 36711632; PubMed Central PMCID: PMC9881845. *Nature*. 2026
5. Alicea Pauneto CDM, Riesenberger BP, Gandy EJ, Kennedy AS, Clutton GT, Hem JW, Hurst KE, Hunt EG, Green JM, Miller BC, Angus SP, Johnson GP, Esther RJ, Gao P, Soto-Pantoja DR, Ferris RL, Modliszewski JL, Coleman MF, Chung HK, Milner JJ, Moschos SJ, Wiseman RL, **Thaxton JE**. Intra-tumoral hypoxia promotes CD8⁺ T cell dysfunction via chronic activation of the integrated stress response transcription factor ATF4. Oct 14;58(10):2489-2504.e8 doi: 10.1016/j.immuni.2025.09.003. *Immunity*. 2025
6. Green WD, Gomez A, Plotkin AL, Pratt BM, Merritt EF, Mullins GN, Kren NP, Modliszewski JL, Zhabotynsky V, Woodcock MG, Green JM, Cannon G, Pipkin ME, Dotti G, **Thaxton JE**, Pylayeva-Gupta Y, Baldwin AS, Morris IV JP, Stanley N, Milner JJ. Enhancer-driven regulatory networks reveal transcription factors governing CD8⁺ T cell differentiation and adaptation in the tumor microenvironment, May 22:S1074-7613(25)00193-1. *Immunity*. 2025
7. Hunt EG, Hurst KE, Riesenberger BP, Kennedy AS, Gandy EJ, Andrews AM, Alicea Pauneto CDM, Ball LE, Wallace ED, Gao P, Meier J, Serody JJ, Coleman MF, **Thaxton JE**. Acetyl-CoA Carboxylase Obstructs CD8⁺ T-Cell Lipid Utilization in the Tumor Microenvironment. Mar 11:S1550-4131(24)00055-X. doi: 10.1016/j.cmet.2024.02.009. *Cell Metabolism*. 2024
8. Rangel Rivera GO, Dwyer CJ, Knochelmann HM, Smith AS, Aksoy BA, Cole AC, Wyatt MM, Kumaresan S, **Thaxton JE**, Lesinski GB, Paulos CM. Progressively enhancing stemness of adoptively transferred T cells with PI3K δ blockade improves metabolism and anti-tumor immunity. Jan 2;84(1):69-83. *Cancer Research*. 2024
9. Riesenberger BP, Hunt EG, Andrews AM, Hurst KE, Tennant MD, Leddy LR, Neskey DM, Hill EG, Gao P, Ball LE, **Thaxton JE**. Stress-mediated translation attenuation undermines T cell tumor control. Dec 2;82(23):4386-4399. doi: 10.1158/0008-5472.CAN-22-1744. PMID: 36126165. *Cancer Research*. 2022
10. Hunt EG, Andrews AM, Larsen S, **Thaxton JE**. The ER-mitochondria Interface as a Dynamic Hub for T Cell Efficacy in Solid Tumors. Apr 27; 10:867341. doi:10.3389/fcell.2022.867341. PMID: 35573704. *Frontiers in Cell and Developmental Biology*. 2022
11. Smith AS, Knochelmann HM, Wyatt MM, Dwyer CJ, Rangel Rivera GO, Rivera Reyes AM, **Thaxton JE**, Barteo EC, Rubinstein MP, Liu B, Paulos CM. B cells imprint adoptively transferred CD8⁺ T cells with enhanced tumor immunity. Jan;10(1):e003078. doi: 10.1136/jitc-2021-003078. PMID: 35017148. *Journal of Immunotherapy of Cancer*. 2022

12. Mehta A, Cheney EM, Hartl C, Pantelidou C, Oliwa M, Castrillon JA, Lin J-R, Hurst, KE, Taveira M, Johnson NT, Oldham WM, Kalocsay M, Berberich MJ, Boswell SA, Kothari A, Johnson S, Dillon DA, Lipschitz M, Rodig S, Santagata S, Garber JE, Tung N, **Thaxton JE**, Mittendorf EA, Sorger PK, Shapiro GI, Guerriero JL. Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRAC1-associated triple-negative breast cancer. Dec; 2, 66-82. *Nature Cancer*. 2021
13. Wallace K, El Nahas GJ, Bookhout C, **Thaxton JE**, Lewin DN, Nikolaishvili-Feinberg N, Cohen SM, Brazeal JG, Hill EG, Wu JD, Baron JA, Alekseyenko AV. Immune responses vary in preinvasive colorectal lesions by tumor location and histology. *cancer*. Sep;14(9):885-892. doi: 10.1158/1940-6207.CAPR-20-0592. PMID: 34341013. *Cancer Prevention Research*. 2021
14. Rangel Rivera GO, Smith AS, Knockelmann HM, Wyatt MM, Dwyer CJ, Rivera Reyes AM, **Thaxton JE**, Paulos CM. Fundamentals of T cell metabolism and strategies to enhance cancer immunotherapy. Mar 18;12:645242. doi: 10.3389/fimmu.2021.645242. PMID: 33815400. *Frontiers in Immunology*. 2021
15. Thomas U. Marron, MD, PhD, Aideen E. Ryan, PhD, Sangeetha M. Reddy, MD, Msci, Sabina Kaczanowska, PhD, Rania H. Younis, BDS, MDS, PhD, Dipti Thakkar, PhD, Jiajia Zhang, MD, MPH, Todd Bartkowiak, PhD, Rachel Howard, PhD, Kristin G. Anderson, PhD, Daniel Olson, MD, Abdul Rafeh Naqash, MD, Ravi B. Patel, MD, PhD, Esha Sachdev, MD, María Esperanza Rodríguez-Ruiz, MD, PhD, Michal Sheffer, PhD, Sarah E. Church, PhD¹⁸, Christopher Fuhrman, PhD¹⁸, Abigail Overacre-Delgoffe, PhD¹⁹, Rosa Nguyen, MD, PhD¹³, Vaia Florou, MD, **Jessica E. Thaxton, PhD**, David H. Aggen, MD, PhD and Jennifer L. Guerriero, PhD. Considerations for treatment duration in responders to immune checkpoint immunotherapy. Mar;9(3):e001901. PMID: 33653801. *Journal of Immunotherapy of Cancer*. 2021
16. Andrews AM, Tennant MD, **Thaxton JE**. Stress relief for cancer immunotherapy: Implications for the ER stress response in tumor immunity. Oct 26; doi: 10.1007/s00262-020-02740-3. PMID: 33104836. *Cancer Immunology and Immunotherapy*. 2020
17. Halbert CH, Jefferson MS, Danielson C, Froeliger B, Giordano A, **Thaxton JE**. An observational study and randomized trial of stress reactivity in cancer disparities. Sep;39(9):745-757. doi: 10.1037/hea0000882. PubMed PMID: 32833476. *Health Psychology*. 2020
18. Dwyer CJ, Arhontoulis DC, Rangel Rivera GO, Knochelmann HM, Smith AS, Wyatt MM, Rubinstein MP, Atkinson C, **Thaxton JE**, Neskey DM, Paulos CM. Ex vivo blockade of PI3K gamma or delta signaling enhances the antitumor potency of adoptively transferred CD8⁺ T cells. May 8;. doi: 10.1002/eji.201948455. PubMed PMID: 32383488. *European Journal of Immunology*. 2020
19. Hurst KE, Lawrence KA, Robino RA, Ball LE, Chung D, **Thaxton JE**. Remodeling Translation Primes CD8⁺ T-cell Antitumor Immunity. May;8(5):587-595. doi: 10.1158/2326-6066.CIR-19-0516. Epub 2020 Feb 19. PubMed PMID: 32075802. *Cancer Immunology Research, Priority Brief*. 2020
20. Hurst KE, Lawrence KA, Reyes Angeles L, Ye Z, Zhang J, Townsend DM, Dolloff N, **Thaxton JE**. Endoplasmic Reticulum Protein Disulfide Isomerase Shapes T Cell Efficacy for Adoptive Cellular Therapy of Tumors. Nov 26;8(12). doi: 10.3390/cells8121514. PubMed PMID: 31779147; PubMed Central PMCID: PMC6953024. *Cells*. 2019
21. Hurst KE, Lawrence KA, Essman MT, Walton ZJ, Leddy LR, **Thaxton JE**. Endoplasmic Reticulum Stress Contributes to Mitochondrial Exhaustion of CD8⁺ T Cells. Mar;7(3):476-486. doi: 10.1158/2326-6066.CIR-18-0182. Epub 2019 Jan 18. PubMed PMID: 30659052; PubMed Central PMCID: PMC6397687. *Cancer Immunology Research*. 2019
22. **Thaxton JE**, Wallace C, Riesenber B, Zhang Y, Paulos CM, Beeson CC, Liu B, Li Z. Modulation of Endoplasmic Reticulum Stress Controls CD4⁺ T-cell Activation and Antitumor Function. Aug;5(8):666-

23. Ansa-Addo EA, **Thaxton JE**, Hong F, Wu BX, Zhang Y, Fugle CW, Metelli A, Riesenber B, Williams K, Gewirth DT, Chiosis G, Liu B, Li Z. Clients and Oncogenic Roles of Molecular Chaperone gp96/grp94. 16(25):2765-78. doi: 10.2174/1568026616666160413141613. Review. PubMed PMID: 27072698; PubMed Central PMCID: PMC5041304. *Current Topics in Medicinal Chemistry*. 2016
24. Zhang Y, Wu BX, Metelli A, **Thaxton JE**, Hong F, Rachidi S, Ansa-Addo E, Sun S, Vasu C, Yang Y, Liu B, Li Z. GP96 is a GARP chaperone and controls regulatory T cell functions. Feb;125(2):859-69. doi: 10.1172/JCI79014. Epub 2015 Jan 20. PubMed PMID: 25607841; PubMed Central PMCID: PMC4319419. *Journal of Clinical Investigation*. 2015
25. **Thaxton JE**, Liu B, Zheng P, Liu Y, Li Z. Deletion of CD24 impairs development of heat shock protein gp96-driven autoimmune disease through expansion of myeloid-derived suppressor cells. Jun 15;192(12):5679-86. doi: 10.4049/jimmunol.1302755. Epub 2014 May 7. PubMed PMID: 24808359; PubMed Central PMCID: PMC4185284. *Journal of Immunology*. 2014
26. **Thaxton JE**, Li Z. To affinity and beyond: harnessing the T cell receptor for cancer immunotherapy. 10(11):3313-21. doi: 10.4161/21645515.2014.973314. Review. PubMed PMID: 25483644; PubMed Central PMCID: PMC4514023. *Human Vaccine and Immunotherapeutics*. 2014
27. **Thaxton JE**, Nevers T, Lippe EO, Blois SM, Saito S, Sharma S. NKG2D blockade inhibits poly(I:C)-triggered fetal loss in wild type but not in IL-10-/- mice. Apr 1;190(7):3639-47. doi: 10.4049/jimmunol.1203488. Epub 2013 Mar 1. PubMed PMID: 23455498; PubMed Central PMCID: PMC3608719. *Journal of Immunology*. 2013
28. **Thaxton JE**, Nevers TA, Sharma S. TLR-mediated preterm birth in response to pathogenic agents. doi: 10.1155/2010/378472. Epub 2010 Aug 23. Review. PubMed PMID: 20827416; PubMed Central PMCID: PMC2933901. *Infect Dis Obstet Gynecol*. 2010
29. **Thaxton JE**, Sharma S. Interleukin-10: a multi-faceted agent of pregnancy. Jun;63(6):482-91. doi: 10.1111/j.1600-0897.2010.00810.x. Epub 2010 Feb 16. Review. PubMed PMID: 20163400; PubMed Central PMCID: PMC3628686. *American Journal of Reproductive Immunology*. 2010
30. **Thaxton JE**, Romero R, Sharma S. TLR9 activation coupled to IL-10 deficiency induces adverse pregnancy outcomes. Jul 15;183(2):1144-54. doi: 10.4049/jimmunol.0900788. PubMed PMID: 19561095; PubMed Central PMCID: PMC2785500. *Journal of Immunology*. 2009
31. Walters S, Webster KE, Sutherland A, Gardam S, Groom J, Liuwantara D, Mariño E, Thaxton J, Weinberg A, Mackay F, Brink R, Sprent J, Grey ST. Increased CD4+Foxp3+ T cells in BAFF-transgenic mice suppress T cell effector responses. Jan 15;182(2):793-801. doi: 10.4049/jimmunol.182.2.793. PubMed PMID: 19124722. *Journal of Immunology*. 2009

Selected Honors & Awards

2026	Mathers Foundation Research Award
2025	Paper of the Year Award, UNC-Chapel Hill
2025	Forbeck Foundation Faculty, Immunometabolism in Cancer Therapy, Mexico
2025	V Foundation Adult Translational Research Award
2023	Developmental Funds Award, UNC-Chapel Hill
2022	Paper of the Year Award, UNC-Chapel Hill
2020	Foundation for Research Development Award, Medical University of South Carolina
2018	Sparkathon Team Winner, Society for Immunotherapy of Cancer
2018	Selected to Sparkathon, Society for Immunotherapy of Cancer
2017	Selected to Immuno-oncology Young Investigators' Forum, Texas

2017	Dean's Nominee, AAMC Young Female Faculty Leadership Series
2017	Harper Drolet Award for Excellence in Sarcoma Research
2017	Young Investigator Award, Society for Immunotherapy of Cancer
2016	NIH/NCI Paul Calabresi Clinical Oncology Fellowship
2013	ESMO Postdoctoral Travel Award, Belgium
2012	Department of Defense Breast Cancer Research Fellowship Award
2011	Early Clinical Investigator Award, Oregon Health & Science University
2010	NIH Ruth Kirschstein NRSA Fellowship, Oregon Health & Science University
2009	SRI Graduate Travel Award, PA
2008	ASRI Graduate Travel Award, IL
2008	ASRI Outstanding New Investigator Award
2007	ISRI Graduate Travel Award, Brazil
2007	Environmental Toxicology Award, Brown University
2006	1 st Place Research Retreat Presentation, Brown University

Select National & International Presentations

2027	Invited Speaker, Feinberg School of Medicine, Northwestern University, Chicago, IL
2026	Invited Keynote Speaker, C-BIO, Valencia, Spain
2026	Visiting Professor, Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC
2026	Invited Speaker, FASEB Organelle Crosstalk Conference, Melbourne, FL
2026	Invited Speaker, Eastern Cooperative Oncology Group-ACRIN, Philadelphia, PA
2026	Invited Speaker, Institute for Molecular Medicine & Biomedical Research, Athens, Greece
2026	Flash Talk, Multifaceted Mitochondria: Cell Press Symposium, Glasgow, Scotland
2026	Invited Speaker, Advancements in Cancer Research and Treatments, Boston, MA
2026	Invited Speaker, Center for Cell Signaling, Rutgers New Jersey Medical School, Newark, NJ
2025	Invited Speaker, Sanford Burnham Prebys, La Jolla, CA
2025	Invited Speaker, Immunometabolism for Cancer Therapy, Forbeck Forum, Mexico City, Mexico
2025	Invited Speaker, FASEB Endoplasmic Reticulum Conference, Melbourne, FL
2024	Invited Speaker, American Society for Hematology Oncology, San Diego, CA
2024	Invited Keynote Speaker, Japanese Society of Immunology, Nagasaki, Japan
2024	Invited Speaker, Wake Forest Baptist Comprehensive Cancer Center, Wake Forest, NC
2024	Winship Elkin Lecturer, Emory University, Atlanta, GA
2024	Invited Speaker, SITC Scientific, Immunometabolism in Cancer Therapy, Miami, FL
2023	Invited Speaker, Agilent Technologies
2023	Invited Speaker, Cancer Drug Discovery, Boston, MA
2023	Invited Speaker, Sanford Burnham Prebys, La Jolla, CA
2022	Invited Speaker, Dana Farber Cancer Center, Boston, MA
2021	Invited Speaker, Lineberger Comprehensive Cancer Center, Chapel Hill, NC
2020	Invited Speaker, Tisch Brain Tumor Center, Duke University, Durham, NC
2020	Invited Speaker, New Mexico Comprehensive Cancer Center, Albuquerque, NM
2018	Invited Speaker, Society for Immunotherapy of Cancer, National Meeting
2018	Invited Speaker, Immune Oncology Young Investigator's Forum, Houston, TX
2018	Invited Speaker, LOWVELO, Hollings Cancer Center Daniel Island, SC

Teaching Activities

2026-2027	Co-Director CBPH706, Dept of Cell Biology & Physiology, UNC Chapel Hill
2025-2026	Co-Director CBPH706, Dept of Cell Biology & Physiology, UNC Chapel Hill
2025-2026	Lecturer, MCRO 731, Dept Microbiology & Immunology, UNC Chapel Hill
2025-2026	Lecturer, CBP853, Dept of Cell Biology & Physiology, UNC Chapel Hill
2024-2025	Co-Director CBPH853, Dept of Cell Biology & Physiology, UNC Chapel Hill
2023-2024	Co-Director CBPH853, Dept of Cell Biology & Physiology, UNC Chapel Hill
2023-2024	Lecturer, MCRO 730, Dept Microbiology & Immunology, UNC Chapel Hill
2022-2023	Co-Director CBPH853, Dept of Cell Biology & Physiology, UNC Chapel Hill

2018-2021	Co-Director, Graduate Introduction to Immunology, MUSC
2016-2020	Lecturer, Basic Orthopedic Science for Clinicians, Department of Orthopedics, MUSC
2016-2021	Lecturer, Translation: Bench to Bedside, Master of Clinical Research, MUSC
2015-2018	Lecturer, Advanced Immunology, Graduate School, MUSC
2007-2009	Teaching Assistant, Introduction to Immunology, School of Medicine, Brown University
2005-2009	Teaching Certificates I, II, III, Sheridan Center for Teaching and Learning, Brown University

Mentee Awards

2026	Jessie Hem	Integrated Translational Oncology Program Grant Award
2025	Samuel Junod, PhD	SPIRE Postdoctoral Fellowship Grant Award
2025	Sumita Trivedi, MD	Robert Winn Career Development Grant Award
2025	Jessie Hem	Integrated Translational Oncology Program Grant Award
2025	Andrew Kennedy	Graduate Fellow in Basic Science Award
2024	Andrew Kennedy	Lineberger Comprehensive Cancer Center Travel Award
2024	Coral del Mar Alicea Pauneto	Pharmacology Scholars Award
2024	Annaleigh Powell-Benton, PhD	SPIRE Postdoctoral Fellowship Grant Award
2023	Coral del Mar Alicea Pauneto	NIH/NCI Supplemental Grant Award
2023	Elizabeth Hunt	SITC Abstract Award
2022	Elizabeth Hunt	SITC Young Investigator Award
2021	Brian Riesenberg, PhD	Immunology Research and Entrepreneurship Grant Award
2020	Alex Andrews, PhD	Integrative Training in Oncogenic Signaling Grant Award

Education

NCI/NIH Paul Calabresi K12 Clinical Oncology Fellowship Hollings Cancer Center, Medical University of South Carolina	2016-2018
Medical University of South Carolina Master of Clinical Research	2014-2015
Department of Defense Breast Cancer Research Program Post-Doctoral Fellowship Knight Cancer Center, Oregon Health & Science University Hollings Cancer Center, Medical University of South Carolina	2012-2015
NIH Ruth Kirschstein Fellowship Department of Microbiology & Immunology, Oregon Health & Science University	2011-2012
Brown University Doctor of Philosophy	2009
Amherst College Bachelor of Arts	2001